Physicians

Department / Division
Pediatrics / Pediatrics-Infectious Diseases

Address
DUMC 3499
Durham, NC 27710

Appointment Telephone
919-668-4000

Office Telephone
919-684-6335

Training

• MD, Duke University School of Medicine, 1999

Residency

• Categorical Pediatrics, Emory University School of Medicine (Georgia), 1999-2002
• Pediatrics, Chief Resident, Emory University School of Medicine (Georgia), 2002-2003

Fellowship

• Pediatric Infectious Diseases, Duke University School of Medicine, 2003-2006

Clinical Interests
General pediatric infectious diseases, pediatric tuberculosis, sexually transmitted infections

Research Interests
Tony Moody, MD is an Assistant Professor in the Department of Pediatrics, Division of Infectious Diseases at Duke University Medical Center. Dr. Moody is the Director of the Laboratory of B cell Immunotechnology at the Duke Human Vaccine Institute (DHVI). Research in the Moody lab is focused on understanding the B cell responses during the earliest stages of HIV infection. The lab has become a resource for human phenotyping, flow characterization, staining and analysis at DHVI. Additionally, Dr. Moody serves as the Chief Medical Officer for the Center for HIV/AIDS Vaccine Immunology (CHAVI) based at Duke. Dr. Moody oversees the CHAVI B Cell Immune Monitoring Core and is the Principal Investigator of the CHAVI 005 and 008A clinical studies. His lab supports the CHAVI 001 and 012 efforts as well.

CHAVI B cell Immune Monitoring Core

The CHAVI B cell Immune Monitoring Core is studying changes to the B cell arm of the immune system during the earliest time points after HIV infection, as early as 17 days after transmission. This group recently elucidated the alterations to B cells that occur during acute/early HIV infection and have submitted a manuscript describing this work.  The Moody lab provides flow cytometry support to the Haynes/Liao group for work on the Antibodyome project.  This cytometric support includes the isolation and phenotyping of cell populations from tissues and blood obtained from CHAVI 012 and single cell sorting of antigen-specific B cells using new dual tetramer labeling technology that can potentially produce new HIV-1 specific monoclonal antibodies.  The lab continues to work on the development of new flow cytometric panels that can enhance the detection of B cell responses during the acute/early HIV infection.

Cross Reactivity of Autoimmune Disease Autoantibodies with HIV Envelope Neutralizing Antibodies (CHAVI 005)

The CHAVI 005 study is investigating the role of autoimmune disease in the ability to make broadly reactive antibodies against HIV.  The Moody lab recently elucidated the mechanism of anti-lipid antibody activity in certain HIV-1 neutralization assays and has submitted a manuscript describing this work.  The group continues to study CHAVI 005 samples looking for anti-cardiolipin antibodies and for the presence of lupus anticoagulant activity and for the potential of these samples to block HIV-1 infection in various assays.

Molecular Characterization of HIV-1 Neutralizing Antibody Breadth and Potency in Natural Infection (CHAVI 008A)

The CHAVI 008A study is designed to obtain clinical material from uninfected and HIV-1 infected patients for method development and pilot study work that is outside the scope of the other CHAVI protocols. The goal of this study is to provide a source of material to develop and optimize new assays and methods without depleting the rare and valuable clinical material obtained in CHAVI 001, 005, 012, and other CHAVI studies. The Moody lab currently processes all samples obtained through the 008A protocol.

CHAVI Tetramer Conjugation Core

The Moody lab also provides B cell tetramer reagents for DHVI groups and CHAVI collaborators as part of the Tetramer Conjugation Core.  They offer custom antibody conjugations for CHAVI pheonotyping work, DHVI work and for other collaborations at Duke.  The lab produces B cell tetramers listed in both PacificBlue and allophycocyanin conjugates, which allows for the simultaneous labeling of B cells and further isolation of the population of interest. The Moody lab has integrated these reagents into their full B cell panel allowing them to select for class-switched B cells so they can isolate memory B cells.

Industry Relationships and Collaborations (What's this?)

This physician has no reported relationships with industry.

Representative Publications
Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L, Gray E, Marshall DJ, Crump JA, Kapiga SH, Sam NE, Sinangil F, Pancera M, Yongping Y, Zhang B, Zhu J, Kwong PD, O'Dell S, Mascola JR, Wu L, Nabel GJ, Phogat S, Seaman MS, Whitesides JF, Moody MA, Kelsoe G, Yang X, Sodroski J, Shaw GM, Montefiori DC, Kepler TB, Tomaras GD, Alam SM, Liao HX, Haynes BF. Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors. J Virol. 2011 Oct;85(19):9998-10009. (2011) Abstract

Ferrari G, Pollara J, Kozink D, Harms T, Drinker M, Freel S, Moody MA, Alam SM, Tomaras GD, Ochsenbauer C, Kappes JC, Shaw GM, Hoxie JA, Robinson JE, Haynes BF. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol. 2011 Jul;85(14):7029-36. (2011) Abstract

Gray ES, Moody MA, Wibmer CK, Chen X, Marshall D, Amos J, Moore PL, Foulger A, Yu JS, Lambson B, Abdool Karim S, Whitesides J, Tomaras GD, Haynes BF, Morris L, Liao HX. Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. J Virol. 2011 Aug;85(15):7719-29. (2011) Abstract

Moody MA, Liao HX, Alam SM, Scearce RM, Plonk MK, Kozink DM, Drinker MS, Zhang R, Xia SM, Sutherland LL, Tomaras GD, Giles IP, Kappes JC, Ochsenbauer-Jambor C, Edmonds TG, Soares M, Barbero G, Forthal DN, Landucci G, Chang C, King SW, Kavlie A, Denny TN, Hwang KK, Chen PP, Thorpe PE, Montefiori DC, Haynes BF. Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. J Exp Med. 2010 Apr 12;207(4):763-76. (2010) Abstract

Bonsignori M, Moody MA, Parks RJ, Holl TM, Kelsoe G, Hicks CB, Vandergrift N, Tomaras GD, Haynes BF. HIV-1 Envelope Induces Memory B Cell Responses That Correlate with Plasma Antibody Levels after Envelope gp120 Protein Vaccination or HIV-1 Infection. J Immunol. 2009 Jul 22. (2009) Abstract

Levesque MC, Moody MA, Hwang KK, Marshall DJ, Whitesides JF, Amos JD, Gurley TC, Allgood S, Haynes BB, Vandergrift NA, Plonk S, Parker DC, Cohen MS, Tomaras GD, Goepfert PA, Shaw GM, Schmitz JE, Eron JJ, Shaheen NJ, Hicks CB, Liao HX, Markowitz M, Kelsoe G, Margolis DM, Haynes BF. Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med. 2009 Jul 7;6(7):e1000107. (2009) Abstract

Liao HX, Levesque MC, Nagel A, Dixon A, Zhang R, Walter E, Parks R, Whitesides J, Marshall DJ, Hwang KK, Yang Y, Chen X, Gao F, Munshaw S, Kepler TB, Denny T, Moody MA, Haynes BF. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J Virol Methods. 2009 Jun;158(1-2):171-9. (2009) Abstract

Alam SM, Scearce RM, Parks RJ, Plonk K, Plonk SG, Sutherland LL, Gorny MK, Zolla-Pazner S, Vanleeuwen S, Moody MA, Xia SM, Montefiori DC, Tomaras GD, Weinhold KJ, Karim SA, Hicks CB, Liao HX, Robinson J, Shaw GM, Haynes BF. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J Virol. 2008 Jan;82(1):115-25. (2008) Abstract

Gasper-Smith N, Crossman DM, Whitesides JF, Mensali N, Ottinger JS, Plonk SG, Moody MA, Ferrari G, Weinhold KJ, Miller SE, Reich CF 3rd, Qin L, Self SG, Shaw GM, Denny TN, Jones LE, Pisetsky DS, Haynes BF. Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design. J Virol. 2008 Aug;82(15):7700-10. (2008) Abstract

Moody MA, Haynes BF. Antigen-specific B cell detection reagents: use and quality control. Cytometry A. 2008 Nov;73(11):1086-92. (2008) Abstract

Roederer M, Moody MA. Polychromatic plots: graphical display of multidimensional data. Cytometry A. 2008 Sep;73(9):868-74. (2008) Abstract

Garges HP, Moody MA, Cotten CM, Smith PB, Tiffany KF, Lenfestey R, Li JS, Fowler VG Jr, Benjamin DK Jr. Neonatal meningitis: what is the correlation among cerebrospinal fluid cultures, blood cultures, and cerebrospinal fluid parameters? Pediatrics. 2006 Apr;117(4):1094-100. (2006) Abstract

Haynes BF, Moody MA, Verkoczy L, Kelsoe G, Alam SM. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum Antibodies. 2005;14(3-4):59-67. (2005) Abstract

Haynes BF, Moody MA, Heinley CS, Korber B, Millard WA, Scearce RM. HIV type 1 V3 region primer-induced antibody suppression is overcome by administration of C4-V3 peptides as a polyvalent immunogen. AIDS Res Hum Retroviruses. 1995 Feb;11(2):211-21. (1995) Abstract